Carisma Therapeutics Inc.

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

Bristol Myers Squibb Company and Sanofi recently joined the ranks of companies cutting costs and jobs in 2024, although not necessarily for the same reasons, as first quarter earnings season got un

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning